PREVENTION MATERNAL TO INFANT HIV TRANSMISSION IN INDIA

描述：（改编自申请人摘要）一项随机临床试验， 母婴艾滋病毒传播的建议，这将直接比较 1200名印度HIV感染妇女接受AZT +3 TC治疗的疗效 在24个月内。此外，治疗时间长短的影响将 还将进行评估：超过40%的该队列将在36周后入组 30%将在分娩时入组。本研究 还将比较产后母体病毒AZT耐药率， 2个治疗组中母亲/婴儿对的发病率和死亡率。在 此外，这项研究将描述促进妇女 参与临床试验，以协助未来的试验，以及 实施临床和行为艾滋病毒预防干预措施。这 研究将提供机会，确定和设计未来干预措施， 并能更迅速地将资源集中在产后的特定原因上， 发展中国家的母婴发病率和死亡率。

DESCRIPTION: (Adapted from applicant's abstract) A randomized clinical trial of maternal-fetal HIV transmission is proposed which will directly compare the efficacy of AZT alone with AZT + 3TC in 1200 HIV-infected Indian women enrolled over a period of 24 months. In addition, the effect of length of therapy will also be assessed: more than 40% of this cohort will be enrolled after 36 weeks of gestation and 30% will be enrolled when they present in labor. This study will also compare the rates of post-partum maternal viral AZT resistance and the morbidity and mortality of mother/infant pairs in the 2 treatment arms. In addition, this study will characterize factors that promote women's participation in clinical trials to assist future trials, as well as implementation of clinical and behavioral HIV prevention interventions. This study will provide an opportunity to identify and design future interventions, and could more rapidly focus resources on specific causes of postpartum morbidity and mortality for mothers and infants in developing countries.